| Magdy Fakhry Giurgius, MBCHB | |
|
2600 Independence Sq, West Plains, MO 65775-4233 | |
| (417) 256-1774 | |
| (417) 256-1794 |
| Full Name | Magdy Fakhry Giurgius |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 29 Years |
| Location | 2600 Independence Sq, West Plains, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184878555 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | IP 1111 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Memorial Hospital Jonesboro, Inc. | Jonesboro, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northeast Arkansas Clinic Charitable Foundation, Inc. | 2961547526 | 228 |
News Archive
W. L. Gore & Associates today announced that the FDA has approved the use of the new GORE Septal Occluder for inclusion in the Gore REDUCE Clinical Study. Gore is introducing this latest technology in its Gore REDUCE Clinical Study for prevention of recurrent stroke in patent foramen ovale (PFO) patients.
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.
The LifeBridge Health Cardiovascular Institute has launched a pilot study to evaluate the potential benefits of a wireless heart monitoring system for patients with moderate to severe heart failure. The system tracks weight, blood pressure and other measures, and automatically sends the information to doctors and staff at the Cardiovascular Institute. The study is looking at whether this approach, designed to be simple and easy-to-use, can result in better outcomes for patients with heart failure.
A new study from UK has found efficacy of psilocybin – a chemical found in "magic mushrooms", in severe depression. The study involved 19 patients with severe depression. The patients took the psilocybin and around half of them improved and reported maintained improvement after 5 weeks of therapy. The patients however also received psychological care along with the treatment.
› Verified 3 days ago
| Entity Name | Northeast Arkansas Clinic Charitable Foundation, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861721839 PECOS PAC ID: 2961547526 Enrollment ID: O20100315000190 |
News Archive
W. L. Gore & Associates today announced that the FDA has approved the use of the new GORE Septal Occluder for inclusion in the Gore REDUCE Clinical Study. Gore is introducing this latest technology in its Gore REDUCE Clinical Study for prevention of recurrent stroke in patent foramen ovale (PFO) patients.
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.
The LifeBridge Health Cardiovascular Institute has launched a pilot study to evaluate the potential benefits of a wireless heart monitoring system for patients with moderate to severe heart failure. The system tracks weight, blood pressure and other measures, and automatically sends the information to doctors and staff at the Cardiovascular Institute. The study is looking at whether this approach, designed to be simple and easy-to-use, can result in better outcomes for patients with heart failure.
A new study from UK has found efficacy of psilocybin – a chemical found in "magic mushrooms", in severe depression. The study involved 19 patients with severe depression. The patients took the psilocybin and around half of them improved and reported maintained improvement after 5 weeks of therapy. The patients however also received psychological care along with the treatment.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Magdy Fakhry Giurgius, MBCHB 2600 Independence Sq, West Plains, MO 65775-4233 Ph: (417) 256-1774 | Magdy Fakhry Giurgius, MBCHB 2600 Independence Sq, West Plains, MO 65775-4233 Ph: (417) 256-1774 |
News Archive
W. L. Gore & Associates today announced that the FDA has approved the use of the new GORE Septal Occluder for inclusion in the Gore REDUCE Clinical Study. Gore is introducing this latest technology in its Gore REDUCE Clinical Study for prevention of recurrent stroke in patent foramen ovale (PFO) patients.
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.
The LifeBridge Health Cardiovascular Institute has launched a pilot study to evaluate the potential benefits of a wireless heart monitoring system for patients with moderate to severe heart failure. The system tracks weight, blood pressure and other measures, and automatically sends the information to doctors and staff at the Cardiovascular Institute. The study is looking at whether this approach, designed to be simple and easy-to-use, can result in better outcomes for patients with heart failure.
A new study from UK has found efficacy of psilocybin – a chemical found in "magic mushrooms", in severe depression. The study involved 19 patients with severe depression. The patients took the psilocybin and around half of them improved and reported maintained improvement after 5 weeks of therapy. The patients however also received psychological care along with the treatment.
› Verified 3 days ago
Bryan Eck, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 805 Kentucky Ave, West Plains, MO 65775 Phone: 417-255-2301 Fax: 417-255-2062 | |
Mr. Stephen H Coats, DO Surgery Medicare: Not Enrolled in Medicare Practice Location: 1115 Alaska, Suite 214, West Plains, MO 65775 Phone: 417-256-9129 Fax: 417-256-8545 | |
David Alejandro Benalcazar Almeida, MD Surgery Medicare: Medicare Enrolled Practice Location: 1100 N Kentucky Ave, West Plains, MO 65775 Phone: 212-939-2976 | |
Dr. Chelsea Rae Fisher, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1100 N Kentucky Ave, West Plains, MO 65775 Phone: 417-256-9111 |